Monopar Therapeutics Files 8-K on Financials

TL;DR

Monopar Therapeutics dropped an 8-K on Nov 8th - check financials.

AI Summary

Monopar Therapeutics Inc. filed an 8-K on November 8, 2024, to report on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This filing provides an update on Monopar Therapeutics' financial health and operational results, which is crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting financial condition and results of operations, without any immediate negative or positive news that would inherently increase risk.

Key Players & Entities

• Monopar Therapeutics Inc. (company) — Registrant
• November 8, 2024 (date) — Date of earliest event reported
• 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Principal executive offices
• 847-388-0349 (phone_number) — Registrant's telephone number

FAQ

From the Filing

0001437749-24-034049.txt : 20241108 0001437749-24-034049.hdr.sgml : 20241108 20241108080231 ACCESSION NUMBER: 0001437749-24-034049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241108 DATE AS OF CHANGE: 20241108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241438054 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20241107_8k.htm FORM 8-K mnpr20241107_8k.htm false 0001645469 0001645469 2024-11-08 2024-11-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): November 8, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒     1     Item 2.02 Results of Operations and Financial Condition   On November 8, 2024, Monopar Therapeutics Inc. ("Monopar" or  the “Company” ) issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of this press release is attached hereto as Exhibit 99.1.   The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to th